The Egyptian pharmaceuticals industry is defensive in nature and enjoys high potential growth supported by an aging population and a prevalence of chronic diseases along with government initiatives of free screening for chronic diseases We expect the Egyptian pharma market to grow at a 5 year CAGR 2020 2025 of 11 8 supported by a 9 6 growth in average selling prices on medicine substitution and the launch of new molecules The local market is underpenetrated in terms of medical insurance, with a low per capita pharma spending of just USD 216 compared to an average of USD 520 in the MENA region, according to the World Bank Government expenditure as a percentage of GDP is merely 4 2 but the government s target is to avail medical insurance to all population by 2032 through the implementation of the Universal Health Care Law ...
